Table 1 Clinical characteristics of reported MS patients (with or without HIV infection) treated with antiretroviral medication
From: Human immunodeficiency virus and multiple sclerosis: a review of the literature
Sex | Age at MS diagnosis | Age at HIV diagnosis | MS type | HIV treatment | Disease-modifying MS therapy | MS course | Follow-up (years) | |
|---|---|---|---|---|---|---|---|---|
(Chalkley & Berger, 2014) [7] | M | 32 | 32 | RRMS | tenofovir, emtricitabine, nelfinavir | none | NEDA | 8 |
(Maruszak et al., 2011) [31] | M | 26 | Months before MS diagnosis | RRMS | combined treatment including nevirapine, stavudine, didanosine, lamivudine | none | Improvement of MS symptoms, no clinical relapses | 2 |
(Maulucci et al., 2015) [32] | F | 19 | 22 | RRMS | tenofovir, emtricitabine, etravirine | Low-dose IFN beta-1a | NEDA-3 | 4 |
(Skarlis et al., 2017) [44] | M | 24 | 36 | RRMS | tenofovir-disorpoxil fumarate, emtricitabine, efavirenz | none | Annualized relapse rate of 0.28, EDSS progression 0.14 | 3 |
(Duran et al., 2004) [14] | M | 32 | 32 | RRMS | efavirenz, zidovudine, lamivudine | none | NEDA | 1.5 |
(Drosu et al., 2018) [13] | F | 25 | No HIV | RRMS | zidovudine, lamivudine | none | NEDA-3 | 3 |